



**HAL**  
open science

## MDSCs in infectious diseases: regulation, roles, and readjustment.

Anca Dorhoi, Estibaliz Glaría, Thalía Garcia-Tellez, Natalie E Nieuwenhuizen, Gennadiy Zelinsky, Benoit Favier, Anurag Singh, Jan Ehrchen, Cornelia Gujer, Christian Münz, et al.

► **To cite this version:**

Anca Dorhoi, Estibaliz Glaría, Thalía Garcia-Tellez, Natalie E Nieuwenhuizen, Gennadiy Zelinsky, et al.. MDSCs in infectious diseases: regulation, roles, and readjustment.. *Cancer Immunology, Immunotherapy*, 2019, 68 (4), pp.673-685. 10.1007/s00262-018-2277-y . pasteur-01969805

**HAL Id: pasteur-01969805**

**<https://pasteur.hal.science/pasteur-01969805>**

Submitted on 4 Jan 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

## MDSC in infectious diseases: regulation, roles and readjustment

Anca Dorhoi<sup>1,2,3\*</sup>, Estibaliz Glaría<sup>4,5</sup>, Thalia Garcia-Tellez<sup>6</sup>, Natalie E. Nieuwenhuizen<sup>3</sup>, Gennadiy Zelinsky<sup>7</sup>, Benoit Favier<sup>8</sup>, Anurag Singh<sup>9</sup>, Jan Ehrchen<sup>10</sup>, Cornelia Gujer<sup>11</sup>, Christian Münz<sup>11</sup>, Margarida Saraiva<sup>12,13</sup>, Yahya Sohrabi<sup>14,15</sup>, Ana E. Sousa<sup>16</sup>, Peter Delpitte<sup>17</sup>, Michaela Müller-Trutwin<sup>6</sup>, Annabel F. Valledor<sup>4,5\*</sup>

<sup>1</sup>Institute of Immunology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.

<sup>2</sup>Faculty of Mathematics and Natural Sciences, University of Greifswald, Greifswald, Germany.

<sup>3</sup>Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.

<sup>4</sup>Nuclear Receptor Group, Department of Cell Biology, Physiology and Immunology, School of Biology, University of Barcelona, Barcelona, Spain.

<sup>5</sup>Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.

<sup>6</sup>Institut Pasteur, HIV Inflammation and Persistence Unit, Paris, France.

<sup>7</sup>Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

<sup>8</sup>CEA – Université Paris Sud 11 – INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, IBJF, Fontenay-aux-Roses, France.

<sup>9</sup>University Children's Hospital and Interdisciplinary Center for Infectious Diseases, University of Tübingen, Tübingen, Germany.

<sup>10</sup>Department of Dermatology, University Hospital Münster, Münster, Germany.

<sup>11</sup>Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.

<sup>12</sup>i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal.

<sup>13</sup>IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.

<sup>14</sup>Molecular and Translational Cardiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.

<sup>15</sup>Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

<sup>16</sup>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

<sup>17</sup>Laboratory of Microbiology, Parasitology and Hygiene (LMPH). Faculty of Pharmaceutical, Biomedical and Veterinary Sciences. University of Antwerp, Antwerp, Belgium.

\*Co-corresponding authors:

Annabel F. Valledor, Department of Cell Biology, Physiology and Immunology, School of Biology, University of Barcelona, Av. Diagonal, 643, 3<sup>rd</sup> floor, 08028 Barcelona, Spain; [afernandezvalledor@ub.edu](mailto:afernandezvalledor@ub.edu);

Anca Dorhoi, Institute of Immunology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Südufer 10, 17493 Greifswald - Insel Riems, Germany; [anca.dorhoi@fli.de](mailto:anca.dorhoi@fli.de)

**ORCID**

Anca Dorhoi: Not available  
Estibaliz Glaría: 0000-0002-5917-9629  
Thalia Garcia-Tellez: 0000-0002-1968-3134  
Natalie E. Nieuwenhuizen: 0000-0001-5749-2462  
Gennadiy Zelinsky: 0000-0001-6338-2382  
Benoit Favier: 0000-0001-9191-6273  
Anurag Singh: 0000-0002-9370-1038  
Jan Ehrchen: Not available  
Cornelia Gujer: Not available  
Christian Münz: 0000-0001-6419-1940  
Margarida Saraiva: 0000-0002-8180-1293  
Yahya Sohrabi: 0000-0001-5268-238X  
Ana E. Sousa: 0000-0002-4618-9799  
Peter Delputte: 0000-0003-3972-616X  
Michaela Muller Trutwin: 0000-0002-3854-2396  
Annabel F. Valledor: 0000-0003-4232-2633

## **Abstract**

Many pathogens, ranging from viruses to multicellular parasites, promote expansion of MDSC, which are myeloid cells that exhibit immunosuppressive features. The roles of MDSC in infection depend on the class and virulence mechanisms of the pathogen, the stage of the disease and the pathology associated with the infection. This work compiles evidence supported by functional assays on the roles of different subsets of MDSC in acute and chronic infections, including pathogen-associated malignancies, and discusses strategies to modulate MDSC dynamics in order to benefit the host.

**Keywords:** Myeloid regulatory cells, MDSC, Infection, Immunosuppression, Oncogenic viruses, Mye-EUNITER

**Précis:** We discuss the roles of MDSC in acute and chronic infection, as well as strategies to modulate their dynamics to benefit the host.

## **Abbreviations**

Arg, arginase

Arm, Armstrong

ATRA, *all-trans* retinoic acid

*B. fragilis*, *Bacteroides fragilis*

*C. albicans*, *Candida albicans*

C13, clone 13

CCR, C-C chemokine receptor  
COST, European Cooperation in Science and Technology  
EBV, Epstein Barr virus  
ETBF, enterotoxigenic *Bacteroides fragilis*  
FV, Friend virus  
*H. felis*, *Helicobacter felis*  
*H. polygyrus*, *Heligmosomoides polygyrus*  
HbsAg, HBV surface antigen  
HDT, host-directed therapy  
IAV, Influenza A virus  
iNKT, invariant NK T  
JEV, Japanese encephalitis virus  
*K. pneumoniae*, *Klebsiella pneumoniae*  
*L. donovani*, *Leishmania donovani*  
*L. major*, *Leishmania major*  
LCMV, lymphocytic choriomeningitis virus  
LOX, lipoxygenase  
*M. tuberculosis*, *Mycobacterium tuberculosis*  
M-MDSC, monocytic MDSC  
MR, mannose receptor  
MRC, myeloid regulatory cells  
mTOR, mammalian target of rapamycin  
NADPH, nicotinamide adenine dinucleotide phosphate  
NOS, NO synthase  
*P. aeruginosa*, *Pseudomonas aeruginosa*  
PcP, *Pneumocystis pneumonia*  
PDE, phosphodiesterase  
PGE2, prostaglandin E2  
PMN-MDSC, neutrophil-like MDSC  
ROS, reactive oxygen species  
*S. aureus*, *Staphylococcus aureus*  
SIV, simian immunodeficiency virus  
*T. crassiceps*, *Taenia crassiceps*  
*T. cruzi*, *Trypanosoma cruzi*  
*T. gondii*, *Toxoplasma gondii*  
TB, tuberculosis  
Tfh, T follicular helper

## Introduction

Myeloid cells recognize pathogens and orchestrate the development of antimicrobial immunity. Sensing of microbial cues initiates the inflammatory response during infectious diseases. These events contribute to the generation of effective adaptive immune responses, pathogen removal, and a return to homeostasis. However, if uncontrolled or unresolved, inflammation results in immunopathology. Pathogen-derived molecules and inflammatory mediators trigger expansion and/or activation of specific subsets of myeloid cells with regulatory activities, termed myeloid regulatory cells (MRC). This differentially affects the disease outcome, depending on the type and stage of the infection involved. MRC include MDSC with either a monocytic (M-MDSC) or a neutrophilic (PMN-MDSC) phenotype, alternatively activated macrophages, and regulatory dendritic cells. Here, we focus specifically on the functions of MDSC in acute and chronic infections, including diseases triggered by oncogenic microbes.

There are limitations to the ways in which the functions of MDSC can be addressed experimentally. An animal devoid of MDSC does not exist, as these cells are generated by myelopoiesis, which will be discussed in more detail below. There is also a lack of studies using genetically modified animals to evaluate the relative contribution of different MDSC populations in infection. However, recent years have provided a wealth of information on the potential functions on MDSC based on correlative studies, *ex vivo* functional assays and drug-induced differentiation of MDSC.

Identification of MDSC relies on phenotypic markers and requires validation of their suppressive activity by immunological assays (1, 2). Here, we discuss interactions of MDSC with selected pathogens using examples in which MDSC subsets have been characterized through functional assays and not only immunophenotyping techniques. We emphasize the relevance of MDSC for the resolution of inflammation and their function as reservoirs for persistent microbes. We highlight microbial signatures and host pathways regulating MDSC dynamics, as well as MDSC capacity to modulate immunopathology in chronic infections and the implications for microbial-induced tumorigenesis. Finally, we address MDSC-targeted strategies and discuss how these could be employed to treat infectious diseases.

## Pathogen and host factors drive MDSC dynamics during infection

Experimental infections and *ex vivo* assays have indicated that selected pathogen-associated molecular patterns trigger expansion of MDSC. In mice, bacterial lipopeptides that bind TLR2/6 (3), LPS (4), which engages TLR4, and flagellin (5), a TLR5 ligand, lead to local or systemic expansion of Gr1<sup>+</sup>CD11b<sup>+</sup> MDSC with proven immunosuppressive properties *ex vivo* and *in vivo*. Viral ligands of TLR2, including HCV core protein (6–9) and HBV surface antigen (HbsAg) (10), both of which are secreted from infected hepatocytes, as well as surface HIV-1 gp120 (11), induce increased numbers of M-MDSC that are able to suppress T cell (6–8, 10, 11) and NK cell responses (9). Such PRR ligands can also drive differentiation of monocytes into MDSC (12). In contrast to TLR2/6, 4 and 5 ligands which lead to expansion of MDSC,

TLR3, 7 or 9 ligands negatively regulate the functionality of MDSC during infection with influenza A virus (IAV) (13, 14).

Fungal pathogens promote the accumulation of PMN-MDSC by activating C-type lectin receptors, notably the dectin-1/Card9 pathway (15). However, purified  $\beta$ -glucans, which are abundant in *Candida spp.* and *Aspergillus spp.* and represent agonists for dectin-1, have been shown to restrict MDSC expansion upon therapeutic delivery in tumor models (16). For this reason, the precise molecular mechanisms by which fungal pathogens promote MDSC genesis requires further characterization.

Some glycans originating from parasites also increase MDSC frequencies in infected tissues. For instance, intraperitoneal injection with intact glycans purified from *Taenia crassiceps* (*T. crassiceps*) or schistosome oligosaccharides elicits myeloid cell populations that suppress T cell proliferation *in vitro* (17–19). Some of these effects are independent of TLR4 and Th2-type cytokines (18, 19). Moreover, immunization of mice with *Toxoplasma gondii* (*T. gondii*) oocyst lysate antigen leads to increased numbers of PMN-MDSC in the lungs (20). However, the host sensors controlling MDSC accumulation in parasitic infections remain to be unveiled.

Besides PRRs, many other host factors affect MDSC dynamics during infection. Several inflammatory mediators and growth factors, including VEGF, GM-CSF, G-CSF, IL-1 $\beta$ , IL-6, TNF- $\alpha$  and prostaglandin E2 (PGE2) have been identified as inducers of MDSC expansion and/or activation (21–23). Among these, the requirement for IL-6 and STAT3 signaling for expansion of MDSC appears to be critical in several unrelated infections (3, 10, 24, 25). As an example, a significant reduction in splenic MDSC accumulation was observed in IL-6-deficient compared to wildtype (WT) mice during *Trypanosoma cruzi* (*T. cruzi*) infection (24). Likewise, mice deficient in hepatic expression of gp130, the common signaling receptor for the IL-6 family of cytokines, showed reduced frequencies of MDSC during polymicrobial sepsis (25). Furthermore, IL-6-induced hepatic acute phase proteins, namely serum amyloid A and chemokine (C-X-C motif) ligand (Cxcl)1, cooperatively promoted mobilization and peripheral accumulation of MDSC (25).

The growth factors GM-CSF and G-CSF control myelopoiesis in the steady state. During dysregulated myelopoiesis, increased levels of these factors leads to continuous activation of progenitors, promoting MDSC generation, particularly in chronic infections (23). Recent findings indicate that GM-CSF drives the conversion of murine Ly6C<sup>hi</sup> and human CD14<sup>+</sup> monocytes into suppressor cells. This differentiation requires activation of the protein kinase B (PKB)/mammalian target of rapamycin (mTOR)/mTOR complex (mTORC)1 pathway by GM-CSF and subsequent signaling through the IFN- $\gamma$  receptor/IFN regulatory factor-1 (IRF-1) pathway (26). Anti-apoptotic molecules, such as cellular-Flice-like inhibitory protein (c-FLIP) and myeloid leukemia cell differentiation protein (MCL-1) play a role in the generation of MDSC during cancer (27), but this has not yet been demonstrated during infection. Overall, it seems that growth factors and cytokines present during an infectious insult may interfere with physiological differentiation of hematopoietic progenitors and result in abnormal cell phenotypes, including MDSC.

Interaction with other immune cells during infection may also influence the frequency and suppressive capacity of MDSC. One example is the more prominent expansion of MDSC in mice deficient in invariant NK T (iNKT) cells compared to control mice during infection with IAV (13). MDSC suppressive activity *in vivo* was abolished by adoptive transfer of iNKT cells, suggesting that interaction between iNKT cells and MDSC modulates MDSC suppressive activity, at least during IAV infection. Whether this pathway operates in other infections remains to be determined.

Taken together, accumulating evidence suggests that selected pathogen sensors and inflammatory mediators mutually or independently activate pathways leading to expansion of MDSC during infection. Additional regulators and the integration of multiple processes that affect MDSC dynamics will presumably be uncovered as research into the biology of these cells in infection is developed.

### **The outcome of MDSC expansion in acute infection**

MDSC subsets appear to exacerbate certain acute infections (Supplementary Table 1) (Figure 1). In viral diseases, MDSC expansion may favor immunosuppression and viral persistence. An example is the inhibition of T follicular helper cells (Tfh) and B cells by MDSC that was observed during infection with a Japanese encephalitis virus (JEV) strain that causes acute encephalopathy (28). Targeting MDSC with retinoic acid reversed suppression and improved the survival of JEV-infected mice. In infection with Friend retrovirus (FV), which is able to persist lifelong in mice despite eliciting a strong acute immune response, expansion of both M-MDSC and PMN-MDSC populations during the late phase of acute infection correlated with CD8<sup>+</sup> T cell contraction. Of these MDSC subsets, experiments *in vitro* suggested that only PMN-MDSC could suppress virus-specific CD8<sup>+</sup> T cell responses (29), although the specific contribution of this subset was not evaluated *in vivo*. Depletion of MDSC rescued activated CD8<sup>+</sup> T cells and minimized viral loads. These observations suggest that MDSC interfere with immune control of the viral load during acute infection, facilitating the subsequent establishment or maintenance of viral chronicity. The expansion of MDSC during acute toxoplasmosis, a parasitic infection, has also been partly associated with immune hyporesponsiveness within the lung (30).

Another scenario in which MDSC expansion may facilitate disease progression is during sepsis. The number of circulating PMN-MDSC in septic patients correlates with the disease severity and with plasma levels of IL-6 (31). In this case, the type of infection may influence the dynamics of different MDSC subsets. M-MDSC were found in all sepsis patients included in a study cohort, whereas PMN-MDSC expanded preferentially in sepsis caused by gram-positive bacteria. Among the neutrophilic subset, a CD14<sup>low</sup> PMN-MDSC population was skewed towards expression of IL-10 and suppressed T cell proliferation *in vitro* through the production of reactive oxygen species (ROS) (32). In a more recent study enrolling patients from intensive care units, PMN-MDSC were specifically expanded in individuals with sepsis and were responsible for increased arginase (Arg) 1 activity (33). High initial frequencies of PMN-MDSC, but not of M-MDSC, were associated with subsequent nosocomial infections. Depletion of

CD15<sup>+</sup> cells from PBMC obtained from sepsis patients increased the rate of T cell proliferation, suggesting that PMN-MDSC may have been largely responsible for the sepsis-induced immune suppression.

The observations in humans diverge from findings in murine models of sepsis. Expansion of MDSC during polymicrobial sepsis induced by cecal ligation was demonstrated to be beneficial for the host (25, 34). Murine MDSC suppressed production of IFN- $\gamma$  by CD8<sup>+</sup> T cells and contributed to sepsis-induced Th2 polarization *in vivo* (34). Mice with reduced levels of circulating and splenic MDSC as a consequence of hepatic gp130 deficiency showed decreased survival after induction of polymicrobial sepsis. The phenotype could be reverted by the adoptive transfer of a heterogeneous population of Gr1<sup>+</sup>CD11b<sup>+</sup> cells comprising 50% PMN-MDSC (25). Together, these studies support a host-protective anti-inflammatory role for MDSC during polymicrobial infections in mice. The discrepancy between observations emerging from humans and murine models may stem from analysis of distinct phases of sepsis as well as from the distinct features of the MDSC subsets involved.

MDSC may also be beneficial for the host in certain acute pneumonia and parasitic infections. During infection with *Klebsiella pneumoniae* (*K. pneumoniae*) tight control of inflammation is critical for pathogen clearance (35). Accumulation of neutrophils in non-resolving pneumonia causes collateral tissue damage, resulting in acute lung injury. In mice infected with *K. pneumoniae*, MDSC were recruited to the lungs several days post challenge and represented an important local source of IL-10, which correlated with the resolution of inflammation and recovery after infection (35). MDSC were shown to efferocytose apoptotic neutrophils, limit inflammation and prevent tissue damage, thereby facilitating the return to tissue homeostasis. In a murine model of Chagas disease, M-MDSC exhibited protective roles as well. They were detected in myocardial lesions during the acute phase of *T. cruzi* infection and suppressed polyclonal T cell proliferation *ex vivo* through a NO-dependent mechanism (36). Furthermore, higher numbers of MDSC were detected in BALB/c compared to C57BL/6 mice during infection, along with lower levels of inflammatory cytokines, reduced liver injury and increased resistance to infection (24). Moreover, decreased MDSC recruitment in IL-6-deficient mice and MDSC depletion both led to increased inflammation, higher parasite burdens and mortality (24). Thus, MDSC-mediated modulation of the inflammatory response during *T. cruzi* infection allowed efficient parasite clearance while simultaneously limiting overzealous adaptive immune responses and excessive tissue damage. In humans suffering from chronic Chagas disease, increased tyrosine nitration was detected on CD8<sup>+</sup> T cells and heightened NO production was shown in peripheral leukocytes (37). Characteristics of MDSC such as activation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and production of NO and peroxynitrites can cause nitration of the TCR and may contribute to their suppressive activity in such conditions. However, whether MDSC expansion influences tyrosine nitration of CD8<sup>+</sup> T cells in humans with Chagas disease remains to be established.

MDSC activity in acute infections can culminate in negative or beneficial outcomes, depending on the microorganism involved as well as the pattern and extent of inflammation. Deleterious effects could result



from host inability to clear pathogens due to immunosuppression, whereas suppression of inflammatory responses that exacerbate tissue damage could be beneficial to the host.

### **The versatile roles of MDSC in chronic infection**

Many successful pathogens manipulate host immunity by suppressing T cell responses, thereby establishing chronic infections. Chronicity poses dual risks. Firstly, it requires prolonged therapy, which often leads to poor patient compliance and the development of antimicrobial resistance. Secondly, it leads to tissue remodeling and the development of microenvironments favoring pathogen persistence. Even when antibiotic therapy is effective and clears the pathogen, infected tissue often fails to reach *restitution ad integrum*, leading to the formation of tissue scars. Such tissue changes and nonresolving inflammation are reminiscent of disease processes in cancer (38). In fact, many types of cancer are associated with particular infectious diseases, with several pathogens so far classified as Group 1 carcinogens (39–41). We will discuss how MDSC affect progression of various infections, including tuberculosis (TB), staphylococcal infections, viral hepatitis, immunodeficiency syndromes, chronic parasitic infections and fungal disorders (Supplementary Table 1) (Figure 1). In addition, we will discuss examples in which MDSC-driven effects have been associated with pathogen-induced tumorigenesis.

An example of a chronic bacterial infection in which MDSC play an important role is active TB, which results predominantly from inefficient T cell responses. Increased frequencies of MDSC are present in pleural fluids from patients with pulmonary TB (42–44), and MDSC isolated from the blood of TB patients suppress T cell function (42, 43), secrete abundant IL-1 $\beta$  and IL-6 (42), and correlate with high NO levels (42, 44). Peripheral MDSC increase in cases of recent, but not remote infection, and a reduction in their frequencies is observed after treatment (43, 44), suggesting that expansion of MDSC correlates with increased bacterial burdens. These findings have been recapitulated in the mouse model of TB, in which MDSC are found in multiple tissues in infected mice (45, 46). These cells harbor *Mycobacterium tuberculosis* (*M. tuberculosis*), and may thus provide a niche for *M. tuberculosis* survival. Furthermore, they release both pro-inflammatory (IL-6, IL-1 $\alpha$ ) and anti-inflammatory (IL-10) cytokines while exerting suppressive effects on T cells (45), including restriction of IFN- $\gamma$  production via NO-dependent mechanisms (46). MDSC may thus support immune evasion by promoting T cell dysfunction and disease progression. Therefore, MDSC qualify as attractive targets for therapeutic intervention, as well as biomarkers of active TB. In support of this, different strategies used to ablate these cells in mice during infection, either alone (45) or in combination with antibiotherapy (47), have resulted in improved disease outcomes. Similar consequences of MDSC depletion were observed in infection with another bacterium, *Staphylococcus aureus* (*S. aureus*) (48). Gemcitabine delivery depleted PMN- and M-MDSC and restored T cell responses. *S. aureus* is frequently associated with orthopedic biofilms that subvert immune-mediated clearance. MDSC represent the main cellular infiltrate in biofilms, as demonstrated in murine models, and their abundance inversely correlates with T cell activity. Biofilm MDSC, but not spleen cells from infected animals, displayed increased Arg1, NOS2 and IL-10 expression, and antibody-mediated depletion of this population improved bacterial clearance by augmenting pro-inflammatory

cytokine release in monocytes and macrophages (48). Hence, MDSC contribute to the chronicity of *S. aureus* biofilm infection.

MDSC may also support oncogenic transformation in infections with bacterial pathogens that can cause colorectal and gastric cancer. In a murine model, infection with *Helicobacter felis* (*H. felis*) caused mobilization of PMN-MDSC to the gastric mucosa and subsequent tissue metaplasia, a precursor of cancer (49). PMN-MDSC were also associated with intestinal metaplasia in human stomach tissue from *Helicobacter pylori*-infected individuals. Similarly, the gut commensal and candidate pathogen enterotoxigenic *Bacteroides fragilis* (ETBF) induced accumulation of MDSC and colon tumorigenesis in a mouse model of colorectal cancer (50). In this study, sorted M-MDSC displayed higher immunosuppressive activity than PMN-MDSC in *ex vivo* assays.

In viral infections, MDSC support the establishment of chronicity. This has been elegantly demonstrated in kinetics experiments with different strains of lymphocytic choriomeningitis virus (LCMV). Comparable levels of expansion of MDSC were observed during the first week of LCMV infection with the Armstrong (Arm) strain, which leads to acute resolving infection, and with clone 13 (C13), which develops into a chronic infection (51). However, only C13 sustained a high number of M-MDSC with suppressive capacity in infected organs. C-C chemokine receptor (CCR)2-deficiency, which diminished mobilization of monocytic cells, or antibody depletion of Gr1<sup>+</sup> cells led to enhanced LCMV-specific T cell cytokine responses in C13-infected mice, suggesting that expansion of suppressive M-MDSC facilitates the establishment of chronicity (51). A detailed analysis of MDSC during chronic infection with LP-BM5 retrovirus, which causes murine acquired immunodeficiency, has also provided evidence for M-MDSC-mediated down-regulation of CD4<sup>+</sup> T cell and B cell responses (52).

HIV induces concomitant immune-regulatory and inflammatory mechanisms that drive chronic viral persistence and disease progression (53, 54). Several studies have quantified MDSC frequencies in different phases of the HIV infection and investigated their interplay with anti-viral immune responses. In patients with primary or chronic HIV-1 infection, expansion of PMN-MDSC with enhanced expression of PD-L1 was already observed during the early primary immune response against HIV (55). *In vitro*, PD-L1 blockade with specific antibodies attenuated the inhibitory function of patient MDSC co-cultured with CD8<sup>+</sup> T cells, suggesting that PD-L1 forms part of their suppressive arsenal. Chronically HIV-1-infected patients showed increased levels of PMN-MDSC that express IL-4 receptor alpha (IL-4R $\alpha$ ). This phenotype positively correlated with the viral load and inversely associated with the CD4<sup>+</sup> T cell count, rapidly changing upon anti-retroviral therapy (56). *In vitro*, MDSC inhibited the proliferation of CD8<sup>+</sup> T cells from both healthy donors and HIV-controllers (HIV-1-infected individuals able to control plasma viral load in the absence of therapy), and induced expansion of Treg from HIV controllers. Another mechanism proposed for PMN-MDSC-mediated suppression in HIV-1 patients is their capability to inhibit CD3 $\zeta$  expression by cell-to-cell contact (57). Increased frequencies of M-MDSC have also been detected in HIV-1 patients despite effective anti-retroviral therapy (58). The suppressive activity of these cells is mediated by Arg1 and cell-to-cell contact, yet their specific contribution to disease

pathophysiology in comparison to that of PMN-MDSC in HIV-1 infection remains elusive. The simian immunodeficiency virus (SIV)-macaque model recapitulates the pathogenesis of HIV infection in humans and is therefore widely used to study the physiopathology of AIDS. In a recent study, SIV infection induced the expansion of CD14<sup>hi</sup>CD16<sup>lo</sup>CCR2<sup>lo</sup> M-MDSC that efficiently suppressed proliferation of CD8<sup>+</sup> T cells, but not of CD4<sup>+</sup> T cells (59). Like in humans, antiretroviral therapy of infected macaques led to contraction of MDSC. Low copy numbers of SIV DNA were found in MDSC of infected macaques, indicating that these cells could constitute a viral reservoir. In a follow-up study looking at the chronic phase of SIV infection before and after anti-retroviral therapy, PMN-MDSC expanded after interruption of treatment. At all stages of infection, isolated PMN-MDSC were able to suppress T cell proliferation (60). Despite clear evidence that MDSC are induced in HIV/SIV infection and that they can inhibit T cell responses, further studies are required to better characterize the dynamics and role of different MDSC subsets in the tissues where immune responses and inflammatory processes take place. Because of their immunosuppressive activity, MDSC may constitute a putative reservoir for pathogens and therefore the permissiveness of this population to HIV infection should be considered.

M-MDSC frequencies were also significantly higher in patients with chronic HCV infection compared to healthy donors (6, 7, 61, 62) or patients receiving antiviral therapy (61, 62). MDSC-induced suppression in HCV infection has often been associated with expression of IL-10 and Arg1 (6, 61, 62). M-MDSC frequency was found to positively correlate with HCV RNA levels (7, 61, 62) and Treg expansion (7). Despite strong evidence that MDSC contribute to T cell impairment, which affects viral clearance in chronic HCV infection, one study challenged this notion by reporting no differences in the frequency of M-MDSC and PMN-MDSC in chronically infected HCV patients and healthy individuals and a lack of correlation between these cells and the viral load (63). In chronic HBV infection, the M-MDSC population expands as well (10, 64) and M-MDSC frequencies correlate positively with HbsAg serum levels (10). *In vitro*, MDSC decreased HBV-specific CD8<sup>+</sup> T cell responses via PD-1-dependent secretion of IL-10 (64). In a mouse model of chronic HBV infection, forced maturation of MDSC by delivery of all-trans retinoic acid (ATRA) limited viral replication (10). In this model, M-MDSC were more efficient at suppressing T cells than PMN-MDSC (65). Their accumulation in the liver was driven by  $\gamma\delta$  T-cells and led to CD8<sup>+</sup> T cell exhaustion (66). In contrast to the findings in mice, higher PMN-MDSC and not M-MDSC frequencies were found in a chronic HBV cohort (67). PMN-MDSC transiently expanded in acute resolving HBV infection and contracted prior to acute liver injury. In persistent infection, Arg-expressing PMN-MDSC increased predominantly in phases characterized by HBV replication without immunopathology and accumulated in the liver, suggesting that PMN-MDSC may restrict liver inflammation (67). MDSC expansion during HBV infection could therefore prevent immunopathology at the cost of promoting chronicity. Whether distinct MDSC subtypes drive such dual outcomes needs further investigation.

Besides favoring chronicity, MDSC abundance correlates with clinical outcome in several virus-associated malignancies. Epstein Barr virus (EBV) is the most growth-transforming pathogen in humans and, accordingly, is associated with human malignancies, mostly of B or epithelial cell origin (68). In

Hodgkin's lymphoma, which is EBV-associated, increased numbers of MDSC in the blood were prognostic of a worse clinical outcome (69). M-MDSC are also present in EBV-associated extranodal natural killer NK/T cell lymphoma (70). In this study, their suppressive function was dependent on NOS2, Arg1 and ROS activities and correlated with elevated expression of immune suppressive cytokines and an increase in Treg. Several viral factors expressed by tumor cells may trigger expansion of functional MDSC, as proposed in studies on EBV-associated nasopharyngeal carcinoma. For example, latent membrane protein 1-mediated glycolysis triggers the activation of p65 and the inflammasome, leading to the production of cytokines critical for MDSC expansion (71).

MDSC also accumulate in chronic parasitic infections, which are commonly associated with the generation of Th2 and Treg responses (72). *Schistosoma japonicum* antigens, for example, enhanced the expansion and suppressive activity of MDSC (73). In this model, immunosuppression was mediated through upregulation of NADPH oxidase subunits and ROS production. MDSC isolated from *Heligmosomoides polygyrus* (*H. polygyrus*)-infected mice, in contrast, used an NO-dependent mechanism for immunosuppression (74). Adoptive transfer of these cells promoted chronic infection with increased worm burdens and egg production.

Like macrophages, M-MDSC may be both classically and alternatively activated depending on their exposure to Th1 or Th2 cytokines and many helminths induce mixed Th1/Th2 responses, at least in certain phases of infection (75). Following implantation with the cestode *T. crassiceps*, IL-4/IL-13 signaling was critical for gradual expansion of MDSC in the peritoneal cavity and acquisition of an alternatively activated phenotype. These cells suppressed T cell proliferation through mechanisms that switched from NO secretion at early stages of infection to a combination of Arg activity, ROS production and generation of peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ) ligands via 12/15-lipoxygenase (LOX) activity in the late phase of infection (76). These results suggest that the mechanisms used by MDSC to limit anti-parasitic adaptive responses may depend of the phase of infection.

The role of MDSCs in chronic infection with other pathogens such as protozoan parasites and fungi has also been investigated. During experimental leishmaniasis, resistant C57BL/6 mice accumulated MDSC which suppressed parasite specific T cell proliferation, but not cytokine release (77). MDSC killed *Leishmania major* (*L. major*) parasites in an NO-dependent manner and enhanced parasite clearance in skin lesions despite decreased parasite-specific T cell proliferation, indicating that MDSC enhanced resistance to *L. major* (77). In agreement with these observations, genetically susceptible BALB/c mice exhibit a reduced ability to recruit CD11b<sup>+</sup>Ly6C<sup>hi</sup> cells to the site of *L. major* infection compared to resistant C57BL/6 mice (78). Thus, genetic conditioning of MDSC function could contribute to disease resistance in murine inbred strains.

The fungal pathogen *Candida albicans* (*C. albicans*) induces a subset of PMN-MDSC during infection in humans and mice (15). *In vitro*, these cells inhibited T cell proliferation, and phagocytosed and killed fungi. In a mouse model of invasive *C. albicans* infection, adoptive transfer of PMN-MDSC effectively

dampened T and NK cell proliferation and improved mouse survival. Notably, different *Candida* species had differential capacities to induce *in vitro* PMN-MDSC expansion and subsequent suppressive activities (79). *Aspergillus fumigatus* also elicits PMN-MDSC (15). However, adoptive transfer of MDSC did not alter viability post-infection in mice. The divergent effects of MDSC in these fungal infections may have been due to the distinct animal models that were employed. *Aspergillus* infection was established in immunocompromised animals, whereas infection with *C. albicans* was performed in immunocompetent mice. MDSC have also been studied in the context of *Pneumocystis pneumonia* (PcP), where they accumulated in the lungs of rodents upon infection and suppressed CD4<sup>+</sup> T cell proliferation *ex vivo* (80). Their frequency correlated with the severity of disease, and adoptive transfer of these cells into healthy mice caused lung damage. ATRA treatment of PcP-infected rats and mice led to diminished MDSC numbers and an increase in alveolar macrophages, which further underlines the deleterious effects of these cells (81). Co-culture studies have suggested that MDSC disable alveolar macrophage function through PD-1/PD-L1 signaling, extending the known MDSC interaction partners to myeloid cells (82).

In summary, during chronic infection MDSC contribute to microbial persistence and, in such instances, pathogens often trigger generation of and benefit from MDSC expansion. However, MDSC may also promote direct pathogen killing by intrinsic effector mechanisms or prevent excessive tissue damage. Additional investigations are required to identify the precise kinetics of distinct MDSC subtypes and unveil how their tissue or lesion compartmentalization influences the course of different infections. MDSC drive tissue metaplasia and are associated with a poor prognosis in cancer. Although it is poorly investigated, the genesis of MDSC in such infections appears to be driven by prolonged inflammation, and possibly by microbial moieties. A comprehensive characterization of MDSC in microbial-induced cancers is essential for the design of novel preventive and therapeutic approaches in this subgroup of malignancies.

### **Targeting MDSC by host-directed interventions for infectious diseases**

Various strategies targeting MDSC have been envisaged, depending on the suggested detrimental or beneficial roles of these cells during a particular infection (Figure 2). In several chronic infections in which MDSC expansion limits protective immunity, depletion of MDSC reversed immunosuppression and improved disease outcome (45, 48). In TB and AIDS, such interventions may in addition remove pathogen reservoirs, as MDSC can harbor these microbes (45, 83). MDSC can be targeted via (i) depletion, (ii) maturation-induced ablation, (iii) interference with their pathways of genesis, and (iv) interference with their suppressive activity.

Antibody-mediated depletion of Gr1<sup>+</sup>Ly6G<sup>+</sup> MDSC-like cells has proven successful in experimental models of TB (45, 84, 85), staphylococcal disease (3, 48) and viral infection (29, 51). Cell depletion is, however, impracticable in humans because MDSC lack unique surface markers and therefore such therapies may affect frequencies and functions of related myeloid populations. Drug-induced depletion of MDSC triggered by cytotoxic agents, including gemcitabine and denileukin diftitox, has been employed

as a proof-of-principle in murine models of *S. aureus* infection (86) and as a host-directed therapy (HDT) complementing canonical chemotherapy in TB (47).

Maturation-induced ablation represents a more attractive option to reduce MDSC frequencies. Various classes of drugs can induce differentiation or maturation of MDSC. ATRA, for example, which induces MDSC differentiation to dendritic cells and macrophages, has been successfully employed in TB. ATRA leads to MDSC ablation and restricts bacterial replication (45), most prominently when given as adjunct to TB chemotherapy (87). ATRA also promotes maturation of HBV-induced MDSC, restores proliferation and IFN- $\gamma$  production of HBV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells from chronically infected patients and prevents viral replication in a mouse model of HBV infection (10). Alternatively, differentiation of MDSC can also be achieved by delivery of  $\beta$ -glucan or low doses of cyclic diguanylate, strategies with proven beneficial effects in cancer (16, 88). Reduction of MDSC can also be accomplished by administration of ceramidase inhibitors, which induce apoptosis through ER-stress and interference with autophagy (89). More recently, activation of liver X receptors has proven efficient in inducing apoptosis of MDSC and has been employed in preclinical models and in human trials for tumor immunotherapy (90). Interference with enzymatic pathways relevant for MDSC-induced suppression represents a complementary intervention for targeting these cells. Phosphodiesterase (PDE) (i.e. PDE5) inhibitors block MDSC suppression by limiting Arg1 and NOS2 expression, and are beneficial as a HDT in TB (91). However, a link to MDSC biology is missing and they may exhibit broad effects on other myeloid cells and additional pathways. Targeting the generation of MDSC is possible with COX2 inhibitors, which block the synthesis of PGE2. These effects may explain the beneficial role of ibuprofen in a TB model characterized by heightened MDSC dynamics (92, 93). In contrast to ablation, drug-induced generation of MDSC has recently been reported. Delivery of finasteride boosts the genesis of suppressor cells (94) and may be employed in infections in which MDSC are beneficial, for instance in acute sepsis or *Pseudomonas aeruginosa* (*P. aeruginosa*) infection (5, 25, 35). Additional studies deciphering the biology of MDSC in infection are required to advance such HDTs into the clinic and for the discovery of novel ways to target these cells therapeutically.

### **General conclusions and Future Perspectives**

The roles of MDSC in fine-tuning the interplay between host and pathogen are being increasingly recognized. As with most myeloid cell subsets, MDSC are endowed with plasticity and thus the search for specificity and commonalities in MDSC biology in infections has just begun. One of the major challenges when dissecting the roles of different MDSC subsets is that a large amount of research is based on a combination of correlation studies *in vivo* and functional assays *ex vivo*. In a study using genetically engineered mice that underwent depletion of either M-MDSC or PMN-MDSC, M-MDSC were identified as the principle immunosuppressive MDSC population in the tumor microenvironment (27). Before experiments using such genetic tools are performed in infections, including those caused by tumorigenic microbes, current conclusions on the relative contribution of specific MDSC populations during infection need to be taken cautiously.

MDSC have nonetheless emerged as targets for HDTs for infectious diseases. The rapid development of antimicrobial resistance advances these cells in the pipeline for the development of novel therapies against drug-resistant microbes. Therapeutic targeting of MDSC in infections with tumorigenic microbes, and the effect on tissue metaplasia, needs to be evaluated. Apart from their therapeutic potential, MDSC have barely been investigated in the context of vaccination. Living organisms, PAMPs, adjuvants and inflammation trigger MDSC generation. Thus, an understanding of whether and how MDSC affect the success of immunizations is needed. This is particularly relevant for newborns and the elderly, as MDSC frequencies are raised in both age groups (95, 96). Lastly, the value of MDSC as biomarkers and their benefits for stratification of patients further justifies accelerating research focused on biology of MDSC in infection and pathogen-associated malignancies.

### **Author contributions**

Conceptualization and writing-original draft: Anca Dorhoi, Estibaliz Glaría, Thalia Garcia-Tellez, Natalie E. Nieuwenhuizen, Gennadiy Zelinsky, Benoit Favier, Anurag Singh, Jan Ehrchen, Cornelia Gujer, Christian Münz, Margarida Saraiva, Yahya Sohrabi, Ana E. Sousa, Peter Delputte, Michaela Müller-Trutwin and Annabel F. Valledor. Figure Design: Anca Dorhoi, Estibaliz Glaría, Thalia Garcia-Tellez and Annabel F. Valledor. Writing-review and editing: Anca Dorhoi, Natalie E. Nieuwenhuizen, Cornelia Gujer and Annabel F. Valledor. Supervision, Anca Dorhoi and Annabel F. Valledor.

### **Acknowledgments**

We thank Ronnie Grant (University of Edimburgh) for figure editing.

### **Funding**

This work was supported by European Cooperation in Science and Technology (COST) and the COST Action BM1404 Mye-EUNITER ([www.mye-euniter.eu](http://www.mye-euniter.eu)). COST is part of the European Union Framework Programme Horizon 2020. Estibaliz Glaría is supported by a fellowship from the University of Barcelona (Ajuts de Personal Investigador predoctoral en Formació, APIF); Thalia Garcia-Tellez is supported by the Institut Carnot Pasteur Maladie Infectieuses (ANR 11-CARN 017-01) as part of the Pasteur - Paris University (PPU) International PhD Program and by Sidaction.

### **Compliance with ethical standards**

#### **Conflict of interest**

The authors declare that they have no conflicts of interest.

### **Ethical approval and ethical standards**

Not applicable.

#### **Informed Consent**

Not applicable.

#### **Animal source**

Not applicable.

#### **Cell line authentication**

Not applicable.

#### **Figure legends**

**Figure 1. Suppressive mechanisms of MDSC in infection.** MDSC subsets exhibit suppressive activities in various infections. Enzymatic pathways, secreted and cell-surface molecules controlling MDSC function are depicted in the context of specific pathogens. The target cells and consequences of MDSC activities are indicated for each infectious agent. Host beneficial and detrimental effects of MDSC are displayed color-coded, in green and red color, respectively.

**Figure 2. Targeting MDSC as part of host-directed interventions against infection.** Four different strategies have been so far envisaged to manipulate MDSC: maturation-induced ablation, depletion, interference with their suppressive activity and promotion of their genesis. Specific drugs for each approach, as well as evidence from particular infectious disease along with the outcome of each immune therapy are summarized. \*, successful method for depletion in mouse model.

Abbreviation: M $\phi$ , macrophage.



## References

1. Bronte V, Brandau S, Chen S-H, et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* 7:12150 . doi: 10.1038/ncomms12150
2. Bruger AM, Dorhoi A, Esendagli G, et al (2018) How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. *Cancer Immunol Immunother*. doi: 10.1007/s00262-018-2170-8
3. Skabytska Y, Wölbing F, Günther C, et al (2014) Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. *Immunity* 41:762–775 . doi: 10.1016/J.IMMUNI.2014.10.009
4. Arora M, Poe SL, Oriss TB, et al (2010) TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. *Mucosal Immunol* 3:578–93 . doi: 10.1038/mi.2010.41
5. Rieber N, Brand A, Hector A, et al (2013) Flagellin Induces Myeloid-Derived Suppressor Cells: Implications for *Pseudomonas aeruginosa* Infection in Cystic Fibrosis Lung Disease. *J Immunol* 190:1276–1284 . doi: 10.4049/jimmunol.1202144
6. Ren JP, Zhao J, Dai J, et al (2016) Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway. *Immunology* 148:377–86 . doi: 10.1111/imm.12616
7. Zhai N, Li H, Song H, et al (2017) Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling. *PLoS One* 12:e0170516 . doi: 10.1371/journal.pone.0170516
8. Tacke RS, Lee H-C, Goh C, et al (2012) Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. *Hepatology* 55:343–53 . doi: 10.1002/hep.24700
9. Goh CC, Roggerson KM, Lee H-C, et al (2016) Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN- $\gamma$  Production by Altering Cellular Metabolism via Arginase-1. *J Immunol* 196:2283–92 . doi: 10.4049/jimmunol.1501881
10. Fang Z, Li J, Yu X, et al (2015) Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. *J Immunol* 195:4873–83 . doi: 10.4049/jimmunol.1501362
11. Garg A, Spector SA (2014) HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. *J Infect Dis* 209:441–51 . doi: 10.1093/infdis/jit469
12. Dorhoi A, Du Plessis N (2018) Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. *Front Immunol* 8:1895 . doi: 10.3389/fimmu.2017.01895
13. De Santo C, Salio M, Masri SH, et al (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. *J*

- Clin Invest 118:4036–4048 . doi: 10.1172/JCI36264
14. Jeisy-Scott V, Davis WG, Patel JR, et al (2011) Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. *PLoS One* 6:e25242 . doi: 10.1371/journal.pone.0025242
  15. Rieber N, Singh A, Öz H, et al (2015) Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. *Cell Host Microbe* 17:507–14 . doi: 10.1016/j.chom.2015.02.007
  16. Albeituni SH, Ding C, Liu M, et al (2016) Yeast-Derived Particulate  $\beta$ -Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. *J Immunol* 196:2167–80 . doi: 10.4049/jimmunol.1501853
  17. Gomez-Garcia L, Lopez-Marin LM, Saavedra R, et al (2005) Intact glycans from cestode antigens are involved in innate activation of myeloid suppressor cells. *Parasite Immunol* 27:395–405 . doi: 10.1111/j.1365-3024.2005.00790.x
  18. Terrazas LI, Walsh KL, Piskorska D, et al (2001) The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. *J Immunol* 167:5294–303
  19. Atochina O, Daly-Engel T, Piskorska D, et al (2001) A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN- $\gamma$  and nitric oxide-dependent mechanism. *J Immunol* 167:4293–302
  20. Wagner A, Schabussova I, Drinic M, et al (2016) Oocyst-Derived Extract of *Toxoplasma Gondii* Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy. *PLoS One* 11:e0155081 . doi: 10.1371/journal.pone.0155081
  21. Ost M, Singh A, Peschel A, et al (2016) Myeloid-Derived Suppressor Cells in Bacterial Infections. *Front Cell Infect Microbiol* 6:37 . doi: 10.3389/fcimb.2016.00037
  22. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* 9:162–74 . doi: 10.1038/nri2506
  23. Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. *Nat Immunol* 19:108–119 . doi: 10.1038/s41590-017-0022-x
  24. Arocena AR, Onofrio LI, Pellegrini A V, et al (2014) Myeloid-derived suppressor cells are key players in the resolution of inflammation during a model of acute infection. *Eur J Immunol* 44:184–94 . doi: 10.1002/eji.201343606
  25. Sander LE, Sackett SD, Dierssen U, et al (2010) Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. *J Exp Med* 207:1453–64 . doi: 10.1084/jem.20091474
  26. Ribechini E, Hutchinson JA, Hergovits S, et al (2017) Novel GM-CSF signals via IFN- $\gamma$ R/IRF-1 and AKT/mTOR license monocytes for suppressor function. *Blood Adv* 1:947–960 . doi: 10.1182/bloodadvances.2017006858

27. Haverkamp JM, Smith AM, Weinlich R, et al (2014) Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways. *Immunity* 41:947–959 . doi: 10.1016/j.immuni.2014.10.020
28. Wang C, Zhang N, Qi L, et al (2017) Myeloid-Derived Suppressor Cells Inhibit T Follicular Helper Cell Immune Response in Japanese Encephalitis Virus Infection. *J Immunol* 199:3094–3105 . doi: 10.4049/jimmunol.1700671
29. Drabczyk-Pluta M, Werner T, Hoffmann D, et al (2017) Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8+ T cell responses during acute Friend retrovirus infection. *Retrovirology* 14:42 . doi: 10.1186/s12977-017-0364-3
30. Voisin M-B, Buzoni-Gatel D, Bout D, Velge-Roussel F (2004) Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. *Infect Immun* 72:5487–92 . doi: 10.1128/IAI.72.9.5487-5492.2004
31. Darcy CJ, Minigo G, Piera KA, et al (2014) Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. *Crit Care* 18:R163 . doi: 10.1186/cc14003
32. Janols H, Bergenfelz C, Allaoui R, et al (2014) A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. *J Leukoc Biol* 96:685–93 . doi: 10.1189/jlb.5HI0214-074R
33. Uhel F, Azzaoui I, Grégoire M, et al (2017) Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. *Am J Respir Crit Care Med* 196:315–327 . doi: 10.1164/rccm.201606-1143OC
34. Delano MJ, Scumpia PO, Weinstein JS, et al (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *J Exp Med* 204:1463–74 . doi: 10.1084/jem.20062602
35. Poe SL, Arora M, Oriss TB, et al (2013) STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. *Mucosal Immunol* 6:189–199 . doi: 10.1038/mi.2012.62
36. Cuervo H, Guerrero NA, Carbajosa S, et al (2011) Myeloid-derived suppressor cells infiltrate the heart in acute *Trypanosoma cruzi* infection. *J Immunol* 187:2656–65 . doi: 10.4049/jimmunol.1002928
37. Sanmarco LM, Visconti LM, Eberhardt N, et al (2016) IL-6 Improves the Nitric Oxide-Induced Cytotoxic CD8+ T Cell Dysfunction in Human Chagas Disease. *Front Immunol* 7:626 . doi: 10.3389/fimmu.2016.00626
38. Nathan C, Ding A (2010) Nonresolving Inflammation. *Cell* 140:871–882 . doi: 10.1016/j.cell.2010.02.029
39. White MK, Pagano JS, Khalili K (2014) Viruses and human cancers: a long road of discovery of molecular paradigms. *Clin Microbiol Rev* 27:463–81 . doi: 10.1128/CMR.00124-13
40. Chang AH, Parsonnet J (2010) Role of bacteria in oncogenesis. *Clin Microbiol Rev* 23:837–57 . doi: 10.1128/CMR.00012-10

41. van Tong H, Brindley PJ, Meyer CG, Velavan TP (2017) Parasite Infection, Carcinogenesis and Human Malignancy. *EBioMedicine* 15:12–23 . doi: 10.1016/j.ebiom.2016.11.034
42. Yang B, Wang X, Jiang J, et al (2014) Identification of CD244-expressing myeloid-derived suppressor cells in patients with active tuberculosis. *Immunol Lett* 158:66–72 . doi: 10.1016/j.imlet.2013.12.003
43. du Plessis N, Loebenberg L, Kriel M, et al (2013) Increased Frequency of Myeloid-derived Suppressor Cells during Active Tuberculosis and after Recent *Mycobacterium tuberculosis* Infection Suppresses T-Cell Function. *Am J Respir Crit Care Med* 188:724–732 . doi: 10.1164/rccm.201302-0249OC
44. El Daker S, Sacchi A, Tempestilli M, et al (2015) Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. *PLoS One* 10:e0123772 . doi: 10.1371/journal.pone.0123772
45. Knaul JK, Jörg S, Oberbeck-Mueller D, et al (2014) Lung-Residing Myeloid-derived Suppressors Display Dual Functionality in Murine Pulmonary Tuberculosis. *Am J Respir Crit Care Med* 190:1053–1066 . doi: 10.1164/rccm.201405-0828OC
46. Tsiganov EN, Verbina EM, Radaeva T V, et al (2014) Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. *J Immunol* 192:4718–27 . doi: 10.4049/jimmunol.1301365
47. Gupta S, Cheung L, Pokkali S, et al (2017) Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis. *J Infect Dis* 215:1883–1887 . doi: 10.1093/infdis/jix208
48. Heim CE, Vidlak D, Scherr TD, et al (2014) Myeloid-Derived Suppressor Cells Contribute to *Staphylococcus aureus* Orthopedic Biofilm Infection. *J Immunol* 192:3778–3792 . doi: 10.4049/jimmunol.1303408
49. Ding L, Hayes MM, Photenhauer A, et al (2016) Schlafen 4-expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia. *J Clin Invest* 126:2867–2880 . doi: 10.1172/JCI82529
50. Thiele Orberg E, Fan H, Tam AJ, et al (2017) The myeloid immune signature of enterotoxigenic *Bacteroides fragilis*-induced murine colon tumorigenesis. *Mucosal Immunol* 10:421–433 . doi: 10.1038/mi.2016.53
51. Norris BA, Uebelhoer LS, Nakaya HI, et al (2013) Chronic but Not Acute Virus Infection Induces Sustained Expansion of Myeloid Suppressor Cell Numbers that Inhibit Viral-Specific T Cell Immunity. *Immunity* 38:309–321 . doi: 10.1016/j.immuni.2012.10.022
52. Green KA, Cook WJ, Green WR (2013) Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. *J Virol* 87:2058–71 . doi: 10.1128/JVI.01547-12
53. Alaoui L, Palomino G, Zurawski S, et al (2017) Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs. *Cell Mol Life Sci* 1–17 . doi: 10.1007/s00018-017-2712-9
54. Huot N, Rasclé P, Garcia-Tellez T, et al (2016) Innate immune cell responses in non pathogenic

- versus pathogenic SIV infections. *Curr Opin Virol* 19:37–44 . doi: 10.1016/j.coviro.2016.06.011
55. Zhang Z-N, Yi N, Zhang T-W, et al (2017) Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection. *JAIDS J Acquir Immune Defic Syndr* 76:200–208 . doi: 10.1097/QAI.0000000000001471
  56. Vollbrecht T, Stirner R, Tufman A, et al (2012) Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. *AIDS* 26:F31–F37 . doi: 10.1097/QAD.0b013e328354b43f
  57. Tumino N, Turchi F, Meschi S, et al (2015) In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3 $\zeta$  expression through ELF-1 inhibition. *AIDS* 29:2397–2407 . doi: 10.1097/QAD.0000000000000871
  58. Qin A, Cai W, Pan T, et al (2013) Expansion of Monocytic Myeloid-Derived Suppressor Cells Dampens T Cell Function in HIV-1-Seropositive Individuals. *J Virol* 87:1477–1490 . doi: 10.1128/JVI.01759-12
  59. Gama L, Shirk EN, Russell JN, et al (2012) Expansion of a subset of CD14<sup>high</sup>CD16<sup>neg</sup>CCR2<sup>low</sup>/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. *J Leukoc Biol* 91:803–816 . doi: 10.1189/jlb.1111579
  60. Dross SE, Munson P V, Kim SE, et al (2017) Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. *J Immunol* 198:757–766 . doi: 10.4049/jimmunol.1600759
  61. Cai W, Qin A, Guo P, et al (2013) Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. *J Clin Immunol* 33:798–808 . doi: 10.1007/s10875-012-9861-2
  62. Zeng Q-L, Yang B, Sun H-Q, et al (2014) Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR  $\zeta$  chain expression on CD8(+) T cells in chronic hepatitis C patients. *Mol Cells* 37:66–73 . doi: 10.14348/molcells.2014.2282
  63. Nonnenmann J, Stirner R, Roeder J, et al (2014) Lack of significant elevation of myeloid-derived suppressor cells in peripheral blood of chronically hepatitis C virus-infected individuals. *J Virol* 88:7678–82 . doi: 10.1128/JVI.00113-14
  64. Huang A, Zhang B, Yan W, et al (2014) Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. *J Immunol* 193:5461–9 . doi: 10.4049/jimmunol.1400849
  65. Chen S, Akbar SMF, Abe M, et al (2011) Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. *Clin Exp Immunol* 166:134–42 . doi: 10.1111/j.1365-2249.2011.04445.x
  66. Kong X, Sun R, Chen Y, et al (2014)  $\gamma\delta$ T cells drive myeloid-derived suppressor cell-mediated CD8<sup>+</sup> T cell exhaustion in hepatitis B virus-induced immunotolerance. *J Immunol* 193:1645–53 . doi: 10.4049/jimmunol.1303432
  67. Pallett LJ, Gill US, Quaglia A, et al (2015) Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. *Nat Med* 21:591–600 . doi: 10.1038/nm.3856

68. Cesarman E (2014) Gammaherpesviruses and Lymphoproliferative Disorders. *Annu Rev Pathol Mech Dis* 9:349–72 . doi: 10.1146/annurev-pathol-012513-104656
69. Romano A, Parrinello NL, Vetro C, et al (2015) Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. *Br J Haematol* 168:689–700 . doi: 10.1111/bjh.13198
70. Zhang H, Li Z-L, Ye S-B, et al (2015) Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. *Cancer Immunol Immunother* 64:1587–1599 . doi: 10.1007/s00262-015-1765-6
71. Cai T-T, Ye S-B, Liu Y-N, et al (2017) LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. *PLOS Pathog* 13:e1006503 . doi: 10.1371/journal.ppat.1006503
72. Maizels RM, McSorley HJ (2016) Regulation of the host immune system by helminth parasites. *J Allergy Clin Immunol* 138:666–675 . doi: 10.1016/j.jaci.2016.07.007
73. Yang Q, Qiu H, Xie H, et al (2017) A *Schistosoma japonicum* Infection Promotes the Expansion of Myeloid-Derived Suppressor Cells by Activating the JAK/STAT3 Pathway. *J Immunol* 198:4716–4727 . doi: 10.4049/jimmunol.1601860
74. Valanparambil RM, Tam M, Jardim A, et al (2017) Primary *Heligmosomoides polygyrus bakeri* infection induces myeloid-derived suppressor cells that suppress CD4+ Th2 responses and promote chronic infection. *Mucosal Immunol* 10:238–249 . doi: 10.1038/mi.2016.36
75. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G (2010) Myeloid-derived suppressor cells in parasitic infections. *Eur J Immunol* 40:2976–85 . doi: 10.1002/eji.201040911
76. Brys L, Beschin A, Raes G, et al (2005) Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. *J Immunol* 174:6095–104 . doi: 10.4049/JIMMUNOL.174.10.6095
77. Pereira WF, Ribeiro-Gomes FL, Guillermo LVC, et al (2011) Myeloid-derived suppressor cells help protective immunity to *Leishmania major* infection despite suppressed T cell responses. *J Leukoc Biol* 90:1191–7 . doi: 10.1189/jlb.1110608
78. Schmid M, Zimara N, Wege AK, Ritter U (2014) Myeloid-derived suppressor cell functionality and interaction with *Leishmania major* parasites differ in C57BL/6 and BALB/c mice. *Eur J Immunol* 44:3295–306 . doi: 10.1002/eji.201344335
79. Singh A, Lelis F, Braig S, et al (2016) Differential Regulation of Myeloid-Derived Suppressor Cells by *Candida* Species. *Front Microbiol* 7:1624 . doi: 10.3389/fmicb.2016.01624
80. Zhang C, Lei G-S, Shao S, et al (2012) Accumulation of myeloid-derived suppressor cells in the lungs during *Pneumocystis pneumonia*. *Infect Immun* 80:3634–41 . doi: 10.1128/IAI.00668-12
81. Lei G-S, Zhang C, Shao S, et al (2013) All-trans retinoic acid in combination with primaquine clears pneumocystis infection. *PLoS One* 8:e53479 . doi: 10.1371/journal.pone.0053479
82. Lei G-S, Zhang C, Lee C-H (2015) Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during *Pneumocystis pneumonia*. *Infect Immun* 83:572–82 . doi: 10.1128/IAI.02686-14
83. Sui Y, Frey B, Wang Y, et al (2017) Paradoxical myeloid-derived suppressor cell reduction in the

- bone marrow of SIV chronically infected macaques. *PLoS Pathog* 13:e1006395 . doi: 10.1371/journal.ppat.1006395
84. Keller C, Hoffmann R, Lang R, et al (2006) Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. *Infect Immun* 74:4295–309 . doi: 10.1128/IAI.00057-06
85. Eruslanov EB, Lyadova I V, Kondratieva TK, et al (2005) Neutrophil responses to *Mycobacterium tuberculosis* infection in genetically susceptible and resistant mice. *Infect Immun* 73:1744–53 . doi: 10.1128/IAI.73.3.1744-1753.2005
86. Tebartz C, Horst SA, Sparwasser T, et al (2015) A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during *Staphylococcus aureus* infection. *J Immunol* 194:1100–11 . doi: 10.4049/jimmunol.1400196
87. Mourik BC, Leenen PJM, de Knecht GJ, et al (2017) Immunotherapy Added to Antibiotic Treatment Reduces Relapse of Disease in a Mouse Model of Tuberculosis. *Am J Respir Cell Mol Biol* 56:233–241 . doi: 10.1165/rcmb.2016-0185OC
88. Chandra D, Quispe-Tintaya W, Jahangir A, et al (2014) STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. *Cancer Immunol Res* 2:901–10 . doi: 10.1158/2326-6066.CIR-13-0123
89. Liu F, Li X, Lu C, et al (2016) Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. *Oncotarget* 7:83907–83925 . doi: 10.18632/oncotarget.13438
90. Tavazoie MF, Pollack I, Tanqueco R, et al (2018) LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. *Cell* 172:825–840.e18 . doi: 10.1016/j.cell.2017.12.026
91. Ahidjo BA, Bishai WR (2016) Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis. *EBioMedicine* 4:7–8 . doi: 10.1016/j.ebiom.2016.02.016
92. Obregón-Henao A, Henao-Tamayo M, Orme IM, Ordway DJ (2013) Gr1(int)CD11b+ myeloid-derived suppressor cells in *Mycobacterium tuberculosis* infection. *PLoS One* 8:e80669 . doi: 10.1371/journal.pone.0080669
93. Vilaplana C, Marzo E, Tapia G, et al (2013) Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. *J Infect Dis* 208:199–202 . doi: 10.1093/infdis/jit152
94. Zhang S, Wu K, Liu Y, et al (2016) Finasteride Enhances the Generation of Human Myeloid-Derived Suppressor Cells by Up-Regulating the COX2/PGE2 Pathway. *PLoS One* 11:e0156549 . doi: 10.1371/journal.pone.0156549
95. Rieber N, Gille C, Köstlin N, et al (2013) Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. *Clin Exp Immunol* 174:45–52 . doi: 10.1111/cei.12143
96. Flores RR, Clauson CL, Cho J, et al (2017) Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF- $\kappa$ B-dependent mechanism. *Aging Cell* 16:480–487 . doi: 10.1111/ace.12571

Figure 1







Figure 2



**Supplementary Table 1. Roles of specific MDSC subsets in acute and chronic infection.** Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; HIF, hypoxia-inducible factor; hm, human; LP, lamina propria; mc, macaque; ms, mouse; Mφ, macrophages; PC, peritoneal cavity; PF, Pleural fluid; rd, rodents; Ref, references.

Pathogen / Disease	Host	Acute / Chronic	Location	MDSC Type	Phenotypic markers	Readout functional assays	Suppressive mechanisms	Outcome	Interventions targeting MDSC	Ref
<i>S. aureus</i>	ms	Acute	Skin, LNs, spleen, blood, BM	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup>	↓T cell proliferation/IFN $\gamma$ production	Cell-cell contact, NOS2	Infection-induced suppression of dermatitis	Depletion (anti-Gr1 Abs)	(3)
		Chronic	Spleen, orthopaedic biofilm	PMN-MDSC	CD11b <sup>+</sup> Ly6G <sup>hi</sup> Ly6C <sup>lo</sup> (Gr1 <sup>+</sup> )	↓T cell proliferation/activation; inflammation; ↑infection	Cell-cell contact; Arg1, NOS2, IL-10	Disease exacerbation; restrict biofilm clearance	Depletion (gemcitabine/anti-Ly6G Abs); MDSC transfer	(48, 86)
			Spleen	M-MDSC	CD11b <sup>+</sup> Ly6G <sup>-</sup> Ly6C <sup>hi</sup>					
<i>P. aeruginosa</i>	hm	Chronic	Blood	PMN-MDSC	IL-4R $\alpha$ <sup>+</sup> CD33 <sup>+</sup> HLA-DR <sup>+</sup> CD66 <sup>hi</sup>	↓T cell proliferation/IL-17 production	ND	Correlation with active disease	ND	(5)
<i>K. pneumoniae</i>	ms	Acute	Lung	PMN-MDSC	CD11b <sup>+</sup> F4/80 <sup>+</sup> Gr1 <sup>+</sup> Ly6G <sup>+</sup> Ly6C <sup>+</sup>	Efferocytosis of apoptotic neutrophils	IL-10	Resolution of inflammation	ND	(35)
<i>M. tuberculosis</i>	ms	Acute	Lung	PMN-MDSC	CD11b <sup>+</sup> Ly6G <sup>+</sup> Gr1 <sup>+</sup>		IL-4R $\alpha$	Indicator of active disease and fatality	Ablation (ATRA); depletion (anti-Gr1 Abs); MDSC transfer	(45, 46)
		Acute / Chronic	Lung, BM, spleen, blood	M-MDSC	CD11b <sup>+</sup> Gr1 <sup>dim</sup> Ly6G <sup>+</sup> F4/80 <sup>+</sup> CD49b <sup>+</sup> Ly6C <sup>+</sup> CD117 <sup>+</sup> CD135 <sup>+</sup>	↓Splenocyte and CD4 <sup>+</sup> T cell proliferation/IFN $\gamma$ production	IL-4R $\alpha$ , NOS2; cell-cell contact			
	hm	Chronic	Lung, PF, blood Lung, blood	MDSC PMN-MDSC	Lin <sup>-</sup> CD11b <sup>+</sup> HLA-DR <sup>+</sup> CD33 <sup>+</sup> CD11b <sup>+</sup> CD14 <sup>+</sup> CD33 <sup>+</sup> CD15 <sup>+</sup> HLA-DR <sup>+</sup>	↓T cell proliferation/cytokine/CD69 expression ↓T cell proliferation	ND NO	Indicator of active disease	ND	(42, 43) (44)
<i>H. felis</i>	ms	Chronic	Stomach	PMN-MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup> Sfmb4 <sup>+</sup> Ly6G <sup>+</sup> Ly6C <sup>+</sup>	↓T cell proliferation	Arg1, NOS2	Correlation with metaplasia	ND	(49)
ETBF	ms	Chronic	Colon tumours	M-MDSC	CD11b <sup>+</sup> Gr1 <sup>+</sup> F4/80 <sup>+</sup> CD11c <sup>+</sup> MHCII <sup>+</sup> SSC <sup>+</sup>	Ag-specific CD8 <sup>+</sup> T cell proliferation	NOS2, IDO1	Association with infection-induced colon tumorigenesis	ND	(50)

EBV	hm	Chronic	Blood	M-MDSC	CD11b <sup>+</sup> CD33 <sup>+</sup> HLA-DR <sup>+</sup> CD14 <sup>+</sup>	CD4 <sup>+</sup> T cell proliferation	NOS2, Arg1, ROS	Correlation with lower overall survival	ND	(70)
IAV	ms	Acute	Lung	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup>	↓Ag-specific splenocyte proliferation	Arg1, NOS2	Suppression of IAV-specific immunity; high viral titer; increased mortality	Transfer of iNKT cells abolish MDSC suppressive activity	(13)
JEV	ms	Acute	Spleen	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup>	↓Tfh cell proliferation; ↓neutralizing Abs	ND	Decreased survival	Ablation (ATRA)	(28)
FV	ms	Acute	Spleen	PMN-MDSC	CD11b <sup>+</sup> Ly6G <sup>+</sup> Ly6C <sup>+</sup>	↓Virus-specific CD8 <sup>+</sup> T cell proliferation and granzyme B production	Arg1, NOS2, PD-L1, CD39	Increased viral load	Depletion (5FU/anti-Ly6G Abs)	(29)
LCMV	ms	Chronic	Spleen	M-MDSC	CD11c <sup>+</sup> CD11b <sup>+</sup> Gr1 <sup>+</sup> Ly6C <sup>+</sup> F4/80 <sup>+</sup> SSC <sup>+</sup>	↓Splenocyte/T cell proliferation; ↓virus-specific cytokine-producing T cells	ND	Indicator of chronic infection	Depletion (anti-Gr1 Abs); mobilization (CCR2 <sup>-/-</sup> mice)	(51)
LP-BM5 retrovirus	ms	Chronic	Spleen	M-MDSC	CD11b <sup>+</sup> Gr1 <sup>+</sup> Ly6C <sup>+</sup> Ly6G <sup>+</sup> HLA-DR <sup>+</sup> CD14 <sup>+</sup> CD33 <sup>+</sup> CD11b <sup>+</sup> (CD15 <sup>+</sup> CD124 <sup>+</sup> )	↓T- and B cell proliferation	NOS2	Susceptibility to infection	ND	(52)
HIV	hm	Primary response/Chronic	Blood	PMN-MDSC	HLA-DR <sup>+</sup> CD11b <sup>+</sup> (CD15 <sup>+</sup> CD124 <sup>+</sup> )	↓CD8 <sup>+</sup> T cell proliferation/IFN- $\gamma$ production; Treg expansion	PD-L1, IL-4R $\alpha$ , suppression of CD3 $\zeta$	Indicator of viral load; negative correlation with CD4 <sup>+</sup> T cell frequencies	ND	(55-57)
		Chronic		M-MDSC	HLA-DR <sup>+</sup> CD11b <sup>+</sup> CD14 <sup>+</sup> CD33 <sup>+</sup> CD15 <sup>+</sup>	↓T cell proliferation/IFN- $\gamma$ production	Arg1; cell-cell contacts			
SIV	mc	Acute/Chronic	Blood	M-MDSC	CD14 <sup>+</sup> CD16 <sup>+</sup> CCR2 <sup>+</sup>	↓Inflammatory cytokines; ↓CD8 <sup>+</sup> T cell proliferation	ND	Indicator of active disease; decreased upon antiretroviral treatment	ND	(59)
			Blood, spleen	PMN-MDSC	CD3 <sup>+</sup> HLA-DR <sup>+</sup> CD11b <sup>+</sup> CD66 <sup>+</sup>	↓T cell proliferation				
HCV	hm	Chronic	Blood, liver	M-MDSC	HLA-DR <sup>+</sup> CD14 <sup>+</sup> CD33 <sup>+</sup> CD11b <sup>+</sup>	Treg expansion; ↓T cell proliferation/IFN- $\gamma$ production	IDO1, PD-L1, HLA-DR, IL-10, Arg1	Indicator of viral RNA and liver damage	ND	(6, 7, 61, 62)

HBV	ms	Chronic	Spleen, liver	M-MDSC PMN-MDSC	CD11b <sup>+</sup> Gr1 <sup>int</sup> Ly6C <sup>hi</sup> Ly6G <sup>+</sup> (F4/80 <sup>+</sup> CD80/86 <sup>+</sup> MHC-II <sup>+</sup> ) CD11b <sup>+</sup> Gr1 <sup>hi</sup> Ly6G <sup>+</sup> Ly6C <sup>lo</sup>	↓T cell proliferation, CD8 <sup>+</sup> CTL function/IFN- $\gamma$ synthesis ↓T cell proliferation	NOS2, Arg1 (M-MDSC); CTLA-4/PD-1 on T cells	Indicator of chronic infection	Depletion (ATRA/anti Gr1 Abs); Arg inhibition; MDSC transfer to TCR $\delta$ <sup>-/-</sup> mice	(10, 65, 66)
	hm	Chronic Acute/Chronic	Blood Blood, liver	M-MDSC PMN-MDSC	HLA-DR <sup>-</sup> CD33 <sup>+</sup> CD11b <sup>+</sup> CD14 <sup>+</sup> CD11b <sup>+</sup> CD33 <sup>+</sup> HLA-DR <sup>+</sup> CD14 <sup>+</sup> CD15 <sup>+</sup>	↓T cell proliferation, IFN- $\gamma$ production, CTL activity	PD-1-induced IL-10 synthesis Arg1	Indicator of viral load; negative correlation with liver pathology Indicator of infection without liver injury	ND	(10, 64) (67)
<i>T. crassiceps</i>	ms	Chronic	PC	MDSC	CD11b <sup>+</sup> Gr1 <sup>+</sup> F4/80 <sup>+</sup>	↓T cell proliferation; IL-4 induction	NOS2, Arg, ROS, 12/15 LOX	Indicator of infection progression	ND	(47)
<i>H. polygyrus</i>	ms	Chronic	LN, spleen, LP	MDSC	F4/80 <sup>+</sup> Gr1 <sup>hi</sup> CD11b <sup>+</sup> Ly6G <sup>+</sup> Ly6C <sup>+</sup> (CD11c <sup>-</sup> )	↓Ag-specific CD4 <sup>+</sup> T-cell proliferation/parasite-specific IL-4 secretion	NOS2	Exacerbation of infection	Transfer of CD11c <sup>+</sup> Gr1 <sup>+</sup> CD11b <sup>+</sup> cells	(74)
<i>L. major</i>	ms	Chronic	PC	MDSC	Gr1 <sup>hi</sup> CD11b <sup>hi</sup>		ND	Enhanced resistance to infection	MDSC transfer; ablation (ATRA)	(77)
			Skin	M-MDSC	CD11b <sup>+</sup> Ly6C <sup>hi</sup> Ly6G <sup>+</sup>	↓T cell proliferation	NOS2	ND	ND	(78)
<i>T. cruzi</i>	ms	Acute	Heart	M-MDSC	CD11b <sup>+</sup> Ly6C <sup>+</sup> Ly6G <sup>-</sup>		NO; L-arginine depletion	Protective role	<i>In vivo</i> inhibition of NOS2; L-arginine supplementation	(36)
			Spleen, liver	MDSC	CD11b <sup>+</sup> Gr1 <sup>+</sup>	↓T cell proliferation	NADPH oxidase; NO/peroxynitrite	Reduced inflammatory cytokines/liver injury; resistance to infection	Depletion (5FU)	(24)
<i>T. gondii</i>	ms	Acute	Lung	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup>	↓Lymphocyte proliferation	NO	Lung defective response	ND	(30)
<i>C. albicans</i>	ms	Acute	Spleen	PMN-MDSC	CD11b <sup>+</sup> Ly6G <sup>+</sup>	↓TNF cell activation/Th17 and TNF $\alpha$ cytokine responses	ND	Increased survival and control of infection	MDSC transfer	(15)
	hm	Chronic	Blood	PMN-MDSC	CD11b <sup>+</sup> CD33 <sup>+</sup> CD14 <sup>+</sup> CXCR4 <sup>+</sup> CD16 <sup>+</sup> CD66b <sup>+</sup>	↓T cell proliferation	ND	ND	ND	

<i>Pneumocystis</i>	rd	Acute	Lung	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup> (ms) CD11b <sup>+</sup> His48 <sup>+</sup> (rat)	↓CD4 <sup>+</sup> T cell proliferation Impaired alveolar Mφ activation/phagocytosis	Arg1, NOS2 PD-1/PD-L1 signaling	Indicator of infection severity; lung damage	PcP MDSC transfer; ablation (ATRA)	(80- 82)
Polymicrobial sepsis	ms	Acute	Liver, spleen, BM, blood, LNs	MDSC	Gr1 <sup>+</sup> CD11b <sup>+</sup>	↓Ag-specific T cell IFNγ synthesis; ↑Th2-linked Abs; restrict Mφ IL-6/IL-12 and boost IL-10	Cell-cell contact	Increased survival; Th2 polarization	Depletion (anti- Gr1 Abs); MDSC transfer	(25, 34)
Sepsis	hm	Acute	Blood	PMN- MDSC	CD11b <sup>+</sup> <sup>hi</sup> CD15 <sup>+</sup> <sup>lo</sup> CD66 <sup>+</sup> CD16 <sup>int</sup> CD45RO <sup>+</sup> CD33 <sup>+</sup> CD14 <sup>+</sup> <sup>lo</sup>	↓T cell proliferation	Arg; ROS; alter T cell ζ-chain expression	Indicator of severity, Gram <sup>+</sup> sepsis and subsequent infections	ND	(31- 33)